Jonathan Sporn, Gilgamesh CEO
May 6, 2021 08:00 AM EDTUpdated May 10, 08:44 PM
Financing

The Har­vard sci­en­tist act­ing as ATAI's trea­sure trove launch­es a new psy­che­delics firm fo­cused on drug 'ana­logues'

Max Gelman

Senior Editor

A for­mer Har­vard and NIH sci­en­tist is re­turn­ing to the psy­che­delics field with a new biotech af­ter sell­ing his last ef­fort to the buzzy ATAI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times